<DOC>
	<DOCNO>NCT02669121</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Norovirus ( NoV ) GI.1/GII.4 Bivalent Virus-Like Particle Vaccine moderate severe acute gastroenteritis ( AGE ) due genotype-specific ( GI.1 GII.4 ) NoV strain .</brief_summary>
	<brief_title>Efficacy Immunogenicity Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine Adults</brief_title>
	<detailed_description>The vaccine test study call NoV GI.1/GII.4 bivalent virus-like particle ( VLP ) vaccine adjuvanted aluminum hydroxide . The norovirus vaccine test prevent acute gastroenteritis ( AGE ) due genotype-specific ( GI.1 GII.4 ) norovirus strain healthy participant recruit US military training installation . This study look illness rate AGE occur &gt; 7 day dose due genotype-specific ( GI.1 GII.4 ) NoV strain represent vaccine . The study enroll 2800 8700 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - NoV GI.1/GII.4 bivalent VLP vaccine - Placebo ( dummy inactive solution ) - liquid look similar study drug active ingredient All participant receive one dose study medication Day 1 administer via intramuscular injection . This multi-center trial conduct United States select military location . The overall time participate study 45 day participant Navy 53 day participant Air Force , 72 day participant Marines . Participants make multiple visit clinic , include final visit last day study participation ( Day 45 , 53 72 ) follow-up assessment .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Participant sign date write , informed consent form require privacy authorization prior initiation trial procedure nature trial explain accord local regulatory requirement . 2 . Male female participant , 18 49 year age . 3 . Is good health time entry trial determine medical history clinical judgment investigator . 4 . Can comply trial procedure available duration followup . 1 . Pregnancy . 2 . Has know hypersensitivity Norovirus ( NoV ) GI.1/GII.4 bivalent viruslike particle ( VLP ) vaccine component ( include excipients ) . 3 . Has know hypersensitivity allergy license require concomitant vaccine component administer ( include excipients vaccine ) . 4 . Has condition circumstance investigator determines would interfere trial evaluation interpretation . 5 . Has know suspect impairment alteration immune function . 6 . Has history acute gastroenteritis ( AGE ) within 14 day enrollment . 7 . Has history body temperature 38.0°C ( 100.4°F ) high within 3 day intend trial vaccination . 8 . Has receive blood , blood product , and/or plasma derivative parenteral immunoglobulin antibody preparation past 3 month . 9 . Immunosuppressive therapy within 3 month systemic ( e.g. , oral parenteral ) corticosteroid treatment within 60 day prior investigational trial dose administration . 10 . Is participate clinical trial another investigational product 30 day prior first trial visit intend participate another clinical trial time conduct trial . 11 . Participants firstdegree relative individual involve conduct trial . 12 . Has history progressive severe neurologic disorder , seizure disorder neuroinflammatory disease ( e.g . GuillainBarré syndrome ) . 13 . Has history illness , opinion investigator , might interfere result trial pose additional risk participant due participation trial . 14 . Has receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment trial exception routine immunization per Military Procedures . 15 . If female childbearing potential , sexually active , use `` acceptable contraceptive method '' least 2 month prior trial entry : 1 . Of childbearing potential defined status post onset menarche meeting follow condition : menopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy , status hysterectomy . 2 . Acceptable birth control method define one following : Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) . Barrier ( condom spermicide diaphragm spermicide ) every time intercourse . Intrauterine device ( IUD ) . Monogamous relationship vasectomize partner . Partner must vasectomize least six month prior participant ' trial entry . 16 . If female childbearing potential sexually active , refusal use `` acceptable contraceptive method '' Day 1 6 month last dose trial vaccine . In addition , must advise donate ova period . 17 . Has positive indeterminate pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>